---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-159393"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2024-06-12T23:59:59+00:00"
generated_at: "2026-06-01T04:51:58.355650+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Setrusumab Phase 2 data: 67% fracture rate reduction in OI at 14 months

## Summary
- Median annualized fracture rate reduced 67% to 0.00 (p=0.0014, n=24) vs pre-treatment 0.72.
- Lumbar spine BMD increased mean 22% at 12 months (p<0.0001, n=19); Z-score improved +1.25 (p<0.0001, n=18).
- No treatment-related serious adverse events or hypersensitivity reactions reported.
- Phase 3 Orbit (158 patients) and Cosmic (69 patients) studies fully enrolled.

## SEC filing metadata
- accession: 0001193125-24-159393
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2024-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312524159393/0001193125-24-159393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312524159393/d849907d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-159393
- JSON: https://secwatch.observer/filing/0001193125-24-159393.json
- Plain text: https://secwatch.observer/filing/0001193125-24-159393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.